193 related articles for article (PubMed ID: 34316172)
1. Clinical Outcome of Patients on Ceftazidime-Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae.
Nagvekar V; Shah A; Unadkat VP; Chavan A; Kohli R; Hodgar S; Ashpalia A; Patil N; Kamble R
Indian J Crit Care Med; 2021 Jul; 25(7):780-784. PubMed ID: 34316172
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates.
Lim TP; Ho JY; Teo JQ; Sim JH; Tan SH; Tan TT; Kwa AL
Microorganisms; 2023 Aug; 11(9):. PubMed ID: 37764002
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
4. Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis.
Prayag PS; Patwardhan SA; Panchakshari S; Sambasivam R; Dhupad S; Soman RN; Prayag AP
Indian J Crit Care Med; 2023 Jun; 27(6):444-450. PubMed ID: 37378372
[TBL] [Abstract][Full Text] [Related]
5.
Yu W; Xiong L; Luo Q; Chen Y; Ji J; Ying C; Liu Z; Xiao Y
Front Cell Infect Microbiol; 2021; 11():780365. PubMed ID: 34900759
[TBL] [Abstract][Full Text] [Related]
6. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo Antimicrobial Activities of Ceftazidime/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales.
Lu G; Tang H; Xia Z; Yang W; Xu H; Liu Z; Ni S; Wang Z; Shen J
Infect Drug Resist; 2022; 15():7107-7116. PubMed ID: 36506837
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the NG-Test Carba 5, Colloidal Gold Immunoassay (CGI) Test, and Xpert Carba-R for the Rapid Detection of Carbapenemases in Carbapenemase-Producing Organisms.
Gu D; Yan Z; Cai C; Li J; Zhang Y; Wu Y; Yang J; Huang Y; Zhang R; Wu Y
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830211
[TBL] [Abstract][Full Text] [Related]
11.
Aslan AT; Ezure Y; Horcajada JP; Harris PNA; Paterson DL
Front Med (Lausanne); 2023; 10():1249030. PubMed ID: 37727767
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant
Zhou J; Yang J; Hu F; Gao K; Sun J; Yang J
Infect Drug Resist; 2020; 13():2571-2578. PubMed ID: 32801794
[TBL] [Abstract][Full Text] [Related]
13. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
14. KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.
Findlay J; Poirel L; Juhas M; Nordmann P
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0089021. PubMed ID: 34228551
[TBL] [Abstract][Full Text] [Related]
15. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
Avery LM; Nicolau DP
Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
[TBL] [Abstract][Full Text] [Related]
16. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis.
Fiore M; Alfieri A; Di Franco S; Pace MC; Simeon V; Ingoglia G; Cortegiani A
Antibiotics (Basel); 2020 Jul; 9(7):. PubMed ID: 32645986
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study.
Rathish B; Wilson A; Warrier A; Prakash S; Babu R; Joy S
Cureus; 2021 Feb; 13(2):e13081. PubMed ID: 33680621
[TBL] [Abstract][Full Text] [Related]
19. In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant
Zou C; Wei J; Shan B; Chen X; Wang D; Niu S
Infect Drug Resist; 2020; 13():3563-3568. PubMed ID: 33116675
[TBL] [Abstract][Full Text] [Related]
20. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
